drugset / Trial / NCT00203073

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

NCT00203073

Phase 2 Completed 40 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupOpen-labelDiagnostic

Summary

It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

Timeline

Start
2003-06
Primary completion
2005-01
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mitoxantrone Small molecule
Comparator Glatiramer Acetate Small molecule 20 mg